1840 PROSTATE VOLUME ADJUSTMENT WITH RECTAL EXAMINATION (DRE) WITHIN THE ERSPC RISK CALCULATOR - The Journal of Urologydoi:10.1016/j.juro.2010.02.1779Roobol, Monique J.Kranse, RiesSchr?der, Fritz H.Elsevier Inc.Journal of Urology
Huang, L., Xu, C., Xu, P., Qin, Y., Chen, M., Feng, Q., … Cheng, Y. (2019). Intelligent photosensitive mesenchymal stem cells and cell-derived microvesicles for photothermal therapy of prostate cancer. Nanotheranostics, 3(1), 41. https://doi.org/10.7150/NTNO.28450 Celikbas, ...
•We established and validated the CPCC risk calculator predicting biopsy result.•This risk calculator incorporated PSA, DRE result, prostate-volume, age, and free PSA ratio.•The AUC for predicting PCa and HGPCa were 0.801 and 0.826, respectively.•This risk calculator outperformed PCPT-RC...
Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehi
Differences between data sets were analyzed using the t-test. Data were expressed as the mean ± standard deviation. The Chi-square test was used to compare categorical variables. A P value < 0.05 was considered as being statistically significant....
We also evaluated the Prostate Cancer Prevention Trial Risk Calculator 2.0 (PCPTRC), which yielded an AUC of 0.62 (95% CI, 0.57-0.67). In addition to the population with an initial biopsy and a PSA level of 2 to 10 ng/mL, we also evaluated performance of the assay in men with a ...
Chiappetta, P. Del Prete, et al. Prostate cancer detection in the “grey area” of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3 Eur Urol, 59 (1) (2011), ...
(p = 0.011). The distribution of prostate volume, tPSA and p2PSA was similar between the two cohorts (all p ≥ 0.19). PHI and %p2PSA were significantly lower in the validation cohort (p < 0.001), as well as the incidence of PCa (p = 0.052) and high-grade ...
Metastatic biopsy programmes combined with advances in genomic sequencing have provided new insights into the molecular landscape of castration-resistant prostate cancer (CRPC), identifying actionable targets, and emerging resistance mechanisms. The dete
Zhang LY, Guo Q, Guan GF, Cheng W, Cheng P, Wu AH. Integrin Beta 5 is a prognostic biomarker and potential therapeutic target in glioblastoma. Front Oncol. 2019;9:904. Article PubMed PubMed Central Google Scholar Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, et al. Control...